Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial

Published:2020-09-08 Issue:10 Volume:72 Page:1607-1620
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Vollenhoven Ronald¹,Takeuchi Tsutomu²,Pangan Aileen L.³,Friedman Alan³,Mohamed Mohamed‐Eslam F.³,Chen Su³,Rischmueller Maureen⁴,Blanco Ricardo⁵^ORCID,Xavier Ricardo M.⁶,Strand Vibeke⁷^ORCID

Affiliation:

1. Amsterdam University Medical Center Amsterdam The Netherlands

2. Keio University School of Medicine Tokyo Japan

3. AbbVie, Inc. North Chicago Illinois USA

4. The Queen Elizabeth Hospital and University of Adelaide Adelaide South Australia Australia

5. Hospital Universitario Marques de Valdecilla and IDIVAL Santander Spain

6. Universidade Federal do Rio Grande do Sul Porto Alegre Rio Grande do Sul Brazil

7. Stanford University Palo Alto California USA

Funder

AbbVie

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41384

Reference37 articles.

1. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

3. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

4. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score

5. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

Cited by 146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: A retrospective cohort study;Seminars in Arthritis and Rheumatism;2024-10

2. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

3. Real-world study comparing the efficacy of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis;Clinical Rheumatology;2024-09-07

4. Upadacitinib to improve anxiety in patients with adalimumab-treated psoriatic arthritis: study protocol for a randomized controlled trial;Trials;2024-09-05

5. Pyrazine-based small molecule kinase inhibitors: clinical applications and patent review (2019–2023);Future Medicinal Chemistry;2024-08-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3